Objective: To provide information regarding the most important properties of the new therapeutic agents marketed in 2001.
Data Sources: Published studies, drug information reference sources, and product labeling.
Data Synthesis: In 2001, 26 new therapeutic agents were marketed. The indications and information on dosage and administration for the new agents are reviewed, as are the most important pharmacokinetic properties, adverse events, drug interactions, and other precautions. Practical considerations for the use of the new agents are also discussed. Where possible, the properties of the new drugs are compared with those of older drugs marketed for the same indications.
Conclusion: A number of the new therapeutic agents marketed in 2001 have important advantages over older medications. An understanding of the properties of these agents is important if the pharmacist is to effectively counsel patients about their use and to serve as a valuable source of information for other health professionals regarding these drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1331/108658002763508524 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomimetic polydopamine loaded with janus kinase inhibitor for synergistic vitiligo therapy via hydrogel microneedles.
J Nanobiotechnology
January 2025
Department of Dermatology and Venereology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Background: Both oxidative stress and autoimmune responses play crucial roles in the development of vitiligo. Under oxidative stress, the apoptotic melanocytes expose self-antigens and release high mobility group box 1 (HMGB1), triggering autoimmune activation and recruiting CD8 T cells. This process further leads to the destruction of melanocytes, resulting in the lack of melanin granules.
View Article and Find Full Text PDFResistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer.
Nat Cancer
January 2025
Department of Oncological Sciences, Precision Immunology Institute, the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cyclin-dependent kinases (CDKs) 4 and 6 (CDK4/6) are important regulators of the cell cycle. Selective CDK4/6 small-molecule inhibitors have shown clinical activity in hormonal receptor-positive (HR) metastatic breast cancer, but their effectiveness remains limited in other cancer types. CDK4/6 degradation and improved selectivity across CDK paralogs are approaches that could expand the effectiveness of CDK4/6 targeting.
View Article and Find Full Text PDFTargeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma.
Leukemia
January 2025
Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.
Multiple myeloma (MM) remains an incurable hematological malignancy that necessitates the identification of novel therapeutic strategies. Here, we report that intracellular levels of very long chain fatty acids (VLCFAs) control the cytotoxicity of MM chemotherapeutic agents. Inhibition of VLCFA biosynthesis reduced cell death in MM cells caused by the proteasome inhibitor, bortezomib.
View Article and Find Full Text PDFDissecting macrophage heterogeneity and kaempferol in lung adenocarcinoma: a single-cell transcriptomic approach and network pharmacology.
Discov Oncol
January 2025
Department of Thoracic Surgery, Shanghai Public Health Clinical Center, Fudan University Shanghai, Caolang Highway 2901#, Jinshan District, Shanghai, People's Republic of China.
Background: Lung adenocarcinoma (LUAD) is a leading form of non-small cell lung cancer characterized by a complex tumor microenvironment (TME) that influences disease progression and therapeutic response. Tumor-associated macrophages (TAMs) within the TME promote tumorigenesis and evasion of immune surveillance, though their heterogeneity poses challenges in understanding their roles and therapeutic targeting. Additionally, traditional Chinese medicine (TCM) offers potential anti-cancer agents that could modulate the immune landscape.
View Article and Find Full Text PDFImpact of iron chelation with deferasirox on telomere length and oxidative stress in hemodialysis patients: A randomized study.
Nefrologia (Engl Ed)
January 2025
Department of Hemodialysis, Hospital General Regional No. 58, Mexican Institute of Social Security, León, Guanajuato, Mexico.
Background: Recent studies have demonstrated the effectiveness, safety, and tolerability of deferasirox in patients in peritoneal dialysis, however, its effect has not been studied in patients undergoing hemodialysis.
Objective: To investigate the impact of iron chelation on telomere length, oxidative stress, and ferritin levels in patients undergoing hemodialysis.
Methods: This is an open-label study, with a control group of patients undergoing hemodialysis, who will receive treatment with deferasirox 15mg/kg/day for 6 months for iron chelation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!